news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

[for the blood products industry, the state has stopped approving new manufacturers since may 2001 and has implemented total quantity control on manufacturers. currently, there are less than 30 blood products manufacturers operating normally in china.]

the blood products industry, where industry concentration continues to increase, has recently seen another merger and acquisition case.

tiantan biological (600161.sh) issued an announcement stating that the company's controlling subsidiary chengdu rongsheng pharmaceutical co., ltd. intends to acquire 100% of the equity of wuhan zhongyuan ruide, a wholly-owned subsidiary of csl behring asia pacific limited [csl asia pacific] for a total amount of us$185 million.

blood products are different from blood and are special "drugs". the 2020 edition of the pharmacopoeia of the people's republic of china clearly states that blood products refer to therapeutic products derived from human blood or plasma, such as human albumin, human immunoglobulin, human coagulation factors, etc.

for the blood products industry, the state has stopped approving new manufacturers since may 2001 and has implemented total quantity control on manufacturers. currently, there are less than 30 blood products manufacturers operating normally in china. mergers and acquisitions have become one of the important means to promote the development and growth of blood products companies. in the context of the continuous strengthening of industry concentration, the integration of industry targets can better expand plasma resources.

according to the semi-annual reports recently disclosed by a number of blood product companies, blood product companies are currently still in a prosperous period amid the relatively sluggish environment of biopharmaceutical companies, but the development of the industry is not without challenges.